FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248351617> ?p ?o ?g. }

• W4248351617 endingPage "72" @default.
• W4248351617 startingPage "60" @default.
• W4248351617 abstract "Dry Eye Syndrome: Basic and Clinical Perspectives Medical treatmentNathaniel Nataneli, Jean SM Chai, Eric Donnenfeld & Henry D PerryNathaniel NataneliNathaniel Nataneli graduated from Albert Einstein College of Medicine in New York (USA). He was a resident and Chief Resident at Bronx–Lebanon Hospital Center (NY, USA) and is currently completing a cornea and external disease fellowship at the Ophthalmic Consultants of Long Island (NY, USA).Search for more papers by this author, Jean SM ChaiJean Chai graduated from the Faculty of Medicine of the National University of Singapore (Singapore). After completing her residency at the Singapore National Eye Center, she continued with a corneal and external eye disease fellowship. She is currently doing her second fellowship in corneal and external eye disease at the Ophthalmic Consultants of Long Island.Search for more papers by this author, Eric DonnenfeldEric Donnenfeld graduated from Dartmouth Medical School (NH, USA) in 1980. He was a resident and Chief Resident at Manhattan Eye, Ear and Throat Hospital (NY, USA) and he completed a Cornea Fellowship at Wills Eye Hospital (PA,USA). He has written over 170 papers on cornea, external disease, cataract and refractive surgery, and 20 book chapters and books. He is on the editorial board of nine journals and has participated in over 40 US FDA studies.Search for more papers by this author & Henry D PerryHenry D Perry graduated from the University of Cincinnati College of Medicine (OH, USA) and completed his internship and residency at Nassau County Medical Center (NY, USA) and the University of Pennsylvania (USA). He completed a fellowship in ophthalmic pathology at the Armed Forces Institute of Pathology (Washington DC, USA) and a fellowship in cornea and external disease at the Massachusetts Eye and Ear Infirmary (USA). He has authored over 180 peer-reviewed articles on diseases and surgery of the cornea and ophthalmic pathology.Search for more papers by this authorPublished Online:24 Jun 2013https://doi.org/10.2217/ebo.13.40AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: There are a variety of medications that are used to treat dry eye disease. The selection of the appropriate treatment plan depends on the type and severity of the dry eye. The most commonly used medication is preserved artificial tears, providing temporary relief for many patients with mild and transient symptoms. For patients with a more significant degree of dry eye, a more targeted approach is often necessary, frequently requiring the use of topical immunomodulation [1]. Examples of such agents are topical cyclosporine and corticosteroids. Patients who exhibit dry eyes with a significant component attributed to evaporative loss often require treatments such as lid hygiene, and macrolide or tetracycline antibiotics. Modification of diet has also shown to be helpful in the management of dry eye. Newer approaches include optimizing the mucin component of the tear film as well as approaches to immunomodulation with agents such as tofacitinib. References1 Perry HD , Solomon R , Donnenfeld ED et al. Evaluation of topical cyclosporine for the treatment of dry eye disease . Arch. Ophthalmol. 126 (8) , 1046 – 1050 (2008) . Crossref, Medline, Google Scholar2 Ousler GW , Michaelson C , Christensen MT . An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops . Cornea 26 (8) , 949 – 952 (2007) . Crossref, Medline, Google Scholar3 McCann LC , Tomlinson A , Pearce EI et al. Effectiveness of artificial tears in the management of evaporative dry eye . Cornea 31 (1) , 1 – 5 (2012) . Crossref, Medline, Google Scholar4 McDonald M , D’Aversa G , Perry HD et al. Correlating patient-reported response to hydroxypropyl cellulose ophthalmic insert (LACRISERT®) therapy with clinical outcomes: tools for predicting response . Curr. Eye Res. 35 (10) , 880 – 887 (2010) . Crossref, Medline, CAS, Google Scholar5 Luchs JI , Nelinson DS , Macy JI et al. Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: findings from a patient registry . Cornea 29 (12) , 1417 – 1427 (2010) . Crossref, Medline, Google Scholar6 Liu Z , Pflugfelder SC . Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency . Ophthalmology 106 (5) , 939 – 943 (1999) . Crossref, Medline, CAS, Google Scholar7 Donnenfeld E , Pflugfelder SC . Topical ophthalmic cyclosporine: pharmacology and clinical uses . Surv. Ophthalmol. 54 (3) , 321 – 338 (2009) . Crossref, Medline, Google Scholar8 Pflugfelder SC . Anti-inflammatory therapy for dry eye . Am. J. Ophthalmol. 137 (2) , 337 – 342 (2004) . Crossref, Medline, Google Scholar9 Perry HD , Donnenfeld ED . Topical 0.05% cyclosporine in the treatment of dry eye . Expert Opin. Pharmacother. 5 (10) , 2099 – 2107 (2004) . Crossref, Medline, CAS, Google Scholar10 Sall K , Stevenson OD , Mundorf TK et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group . Ophthalmology 107 (4) , 631 – 639 (2000) . Crossref, Medline, CAS, Google Scholar11 Su MY , Perry HD , Barsam A et al. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy . Cornea 30 (10) , 1098 – 1104 (2011) . Crossref, Medline, Google Scholar12 Dastjerdi MH , Hamrah P , Dana R . High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen . Cornea 28 (10) , 1091 – 1096 (2009) . Crossref, Medline, Google Scholar13 Perry HD , Doshi-Carnevale S , Donnenfeld ED et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction . Cornea 25 (2) , 171 – 175 (2006) . Crossref, Medline, Google Scholar14 Rubin M , Rao SN . Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis . J. Ocul. Pharmacol. Ther. 22 (1) , 47 – 53 (2006) . Crossref, Medline, CAS, Google Scholar15 Byun YJ , Kim TI , Kwon SM et al. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye . Cornea 31 (5) , 509 – 513 (2012) . Crossref, Medline, Google Scholar16 Hong S , Kim T , Chung SH et al. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren’s syndrome . J. Ocul. Pharmacol. Ther. 23 (1) , 78 – 82 (2007) . Crossref, Medline, CAS, Google Scholar17 Avisar R , Robinson A , Appel I et al. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis . Cornea 19 (2) , 145 – 147 (2000) . Crossref, Medline, CAS, Google Scholar18 Aragona P , Stilo A , Ferreri F et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren’s syndrome patients . Eye (Lond.). 19 (5) , 535 – 539 (2005) . Crossref, Medline, CAS, Google Scholar19 Geerling G , Maclennan S , Hartwig D . Autologous serum eye drops for ocular surface disorders . Br. J. Ophthalmol. 88 (11) , 1467 – 1474 (2004) . Crossref, Medline, CAS, Google Scholar20 Fox RI , Chan R , Michelson JB et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca . Arthritis Rheum. 27 (4) , 459 – 461 (1984) . Crossref, Medline, CAS, Google Scholar21 Kojima T , Higuchi A , Goto E et al. Autologous serum eye drops for the treatment of dry eye diseases . Cornea 27 , S25 – S30 (2008) . Crossref, Medline, Google Scholar22 Matsumoto Y , Dogru M , Goto E et al. Autologous serum application in the treatment of neurotrophic keratopathy . Ophthalmology 111 (6) , 1115 – 1120 (2004) . Crossref, Medline, Google Scholar23 Quinto GG , Campos M , Behrens A . Autologous serum for ocular surface diseases . Arq. Bras. Oftalmol. 71 (Suppl. 6) , S47 – S54 (2008) . Crossref, Medline, Google Scholar24 Kojima T , Ishida R , Dogru M et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case–control study . Am. J. Ophthalmol. 139 (2) , 242 – 246 (2005) . Crossref, Medline, Google Scholar25 Noble BA , Loh RS , MacLennan S et al. Comparison of autologous serum eye drops with conventional therapy in a randomized controlled crossover trial for ocular surface disease . Br. J. Ophthalmol. 88 (5) , 647 – 652 (2004) . Crossref, Medline, CAS, Google Scholar26 Luchs J . Azithromycin in DuraSite for the treatment of blepharitis . Clin. Ophthalmol. 30 , 681 – 688 (2010) . Crossref, Google Scholar27 Foulks GN , Borchman D , Yappert M et al. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study . Cornea 32 (1) , 44 – 53 (2013) . Crossref, Medline, Google Scholar28 Paranjpe DR , Foulks GN . Therapy for meibomian gland disease . Ophthalmol. Clin. North Am. 16 (1) , 37 – 42 (2003) . Crossref, Medline, Google Scholar29 Dougherty JM , McCulley JP , Silvany RE et al. The role of tetracycline in chronic blepharitis: inhibition of lipase production in staphylococci . Invest. Ophthalmol. Vis. Sci. 32 (11) , 2970 – 2975 (1991) . Medline, CAS, Google Scholar30 Shine WE , McCulley JP . Meibomian gland in chronic blepharitis . Adv. Exp. Med. Biol. 438 , 319 – 326 (1998) . Crossref, Medline, Google Scholar31 McCulley JP , Shine WE . Changing concepts in the diagnosis and management of blepharitis . Cornea 19 (5) , 650 – 658 (2000) . Crossref, Medline, CAS, Google Scholar32 Iovieno A , Lambiase A , Micera A et al. In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis . Eur. J. Ophthalmol. 19 (5) , 708 – 716 (2009) . Crossref, Medline, Google Scholar33 Perry HD , Hodes LW , Seedor JA et al. Effect of doxycycline hyclate on corneal epithelial wound healing in the rabbit alkali-burn model. Preliminary observations . Cornea 12 (5) , 379 – 382 (1993) . Crossref, Medline, CAS, Google Scholar34 Luchs J . Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis . Adv. Ther. 25 (9) , 858 – 870 (2008) . Crossref, Medline, CAS, Google Scholar35 Igami TZ , Holzchuh R , Osaki TH . Oral azithromycin for treatment of posterior blepharitis . Cornea 30 (10) , 1145 – 1149 (2011) . Crossref, Medline, Google Scholar36 Foulks GN , Borchman D , Yappert M et al. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations . Cornea 29 (7) , 781 – 788 (2010) . Crossref, Medline, Google Scholar37 Rand AL , Asbell PA . Nutritional supplements for dry eye syndrome . Curr. Opin. Ophthalmol. 22 (4) , 279 – 282 (2011) . Crossref, Medline, Google Scholar38 Zoukhri D , Kublen CL . Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren’s syndrome . Invest. Ophthalmol. Vis. Sci. 42 (5) , 925 – 932 (2001) . Medline, CAS, Google Scholar39 Zoukhri D , Hodges RR , Byon D et al. Role of proinflammatory cytokines in the impaired lacrimation associated with autoimmune xerophthalmia . Invest. Ophthalmol. Vis. Sci. 43 (5) , 1429 – 1436 (2002) . Medline, Google Scholar40 Zejin Z , Stevenson D , Schechter JE et al. Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis . Cornea 22 (4) , 343 – 351 (2003) . Medline, Google Scholar41 Wojtowicz JC , Butovich I , Uchiyama E et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an Ω-3 supplement for dry eye . Cornea 30 (3) , 308 – 314 (2011) . Crossref, Medline, Google Scholar42 Pisella PJ , Brignole F , Debbasch C et al. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca . Ophthalmology 107 (10) , 1841 – 1849 (2000) . Crossref, Medline, CAS, Google Scholar43 Barabino S , Rolando M , Camicione P et al. Systemic linoleic and γ-linolenic acid therapy in dry eye syndrome with an inflammatory component . Cornea 22 (2) , 97 – 101 (2003) . Crossref, Medline, Google Scholar44 Akpek EK , Lindsley KB , Adyanthaya RS et al. Treatment of Sjögren’s syndrome-associated dry eye an evidence-based review . Ophthalmology 118 (7) , 1242 – 1252 (2011) . Medline, Google Scholar45 Matsumoto Y , Ohashi Y , Watanabe H et al. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese Phase 2 clinical trial . Ophthalmology 119 (10) , 1954 – 1960 (2012) . Crossref, Medline, Google Scholar46 Takeji Y , Urashima H , Aoki A et al. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells . J. Ocul. Pharmacol. Ther. 28 (3) , 259 – 263 (2012) . Crossref, Medline, CAS, Google Scholar47 Huang JF , Yafawi R , Zhang M et al. Immunomodulatory effect of the topical ophthalmic janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease . Ophthalmology 119 (7) , E43 – E50 (2012) . Crossref, Medline, Google Scholar48 Scott G , Yiu SC , Wasilewski D et al. Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women . Am. J. Ophthalmol. 139 (6) , 1109 – 1110 (2005) . Crossref, Medline, CAS, Google ScholarWebsite101 Abelson MB, Kumar R, Sleeper A. All you need to make an artificial tear. Review of Ophthalmology (2003). www.revophth.com/content/d/therapeutic_topics/i/1338/c/25639 Google ScholarFiguresReferencesRelatedDetails Dry Eye Syndrome: Basic and Clinical PerspectivesMetrics Downloaded 28 times History Published online 24 June 2013 Published in print June 2013 Information© Future Medicine Ltd© Future Medicine LtdPDF download" @default.
• W4248351617 created "2022-05-12" @default.
• W4248351617 creator A5044263503 @default.
• W4248351617 creator A5059109350 @default.
• W4248351617 creator A5087351188 @default.
• W4248351617 creator A5002606049 @default.
• W4248351617 date "2013-06-01" @default.
• W4248351617 modified "2023-09-27" @default.
• W4248351617 title "Medical treatment" @default.
• W4248351617 cites W1490720169 @default.
• W4248351617 cites W1523354060 @default.
• W4248351617 cites W1818249676 @default.
• W4248351617 cites W1918323027 @default.
• W4248351617 cites W1966632162 @default.
• W4248351617 cites W1967987864 @default.
• W4248351617 cites W1972501597 @default.
• W4248351617 cites W1980162009 @default.
• W4248351617 cites W1981921982 @default.
• W4248351617 cites W1982934791 @default.
• W4248351617 cites W1983814066 @default.
• W4248351617 cites W1987397884 @default.
• W4248351617 cites W1988869571 @default.
• W4248351617 cites W1991945678 @default.
• W4248351617 cites W1992873140 @default.
• W4248351617 cites W1993050768 @default.
• W4248351617 cites W1993713029 @default.
• W4248351617 cites W2003272769 @default.
• W4248351617 cites W2010052469 @default.
• W4248351617 cites W2010052599 @default.
• W4248351617 cites W2010542723 @default.
• W4248351617 cites W2012582550 @default.
• W4248351617 cites W2021835818 @default.
• W4248351617 cites W2021968547 @default.
• W4248351617 cites W2022003523 @default.
• W4248351617 cites W2029596539 @default.
• W4248351617 cites W2029793768 @default.
• W4248351617 cites W2045978101 @default.
• W4248351617 cites W2047269513 @default.
• W4248351617 cites W2058437325 @default.
• W4248351617 cites W2059913027 @default.
• W4248351617 cites W2061620519 @default.
• W4248351617 cites W2062202268 @default.
• W4248351617 cites W2067494913 @default.
• W4248351617 cites W2068244886 @default.
• W4248351617 cites W2074056511 @default.
• W4248351617 cites W2083762757 @default.
• W4248351617 cites W2084906081 @default.
• W4248351617 cites W2088119156 @default.
• W4248351617 cites W2088344821 @default.
• W4248351617 cites W2093105335 @default.
• W4248351617 cites W2093220756 @default.
• W4248351617 cites W2093520231 @default.
• W4248351617 cites W2100916895 @default.
• W4248351617 cites W2108823359 @default.
• W4248351617 cites W2112482290 @default.
• W4248351617 cites W2122427974 @default.
• W4248351617 cites W2124784965 @default.
• W4248351617 cites W2126358511 @default.
• W4248351617 cites W2132431323 @default.
• W4248351617 cites W2135702688 @default.
• W4248351617 cites W2138988829 @default.
• W4248351617 cites W2151640822 @default.
• W4248351617 cites W2156030957 @default.
• W4248351617 cites W2197279029 @default.
• W4248351617 cites W2318387698 @default.
• W4248351617 cites W2331750532 @default.
• W4248351617 cites W2333474664 @default.
• W4248351617 cites W2596391620 @default.
• W4248351617 doi "https://doi.org/10.2217/ebo.13.40" @default.
• W4248351617 hasPublicationYear "2013" @default.
• W4248351617 type Work @default.
• W4248351617 citedByCount "0" @default.
• W4248351617 crossrefType "other" @default.
• W4248351617 hasAuthorship W4248351617A5002606049 @default.
• W4248351617 hasAuthorship W4248351617A5044263503 @default.
• W4248351617 hasAuthorship W4248351617A5059109350 @default.
• W4248351617 hasAuthorship W4248351617A5087351188 @default.
• W4248351617 hasConcept C71924100 @default.
• W4248351617 hasConceptScore W4248351617C71924100 @default.
• W4248351617 hasLocation W42483516171 @default.
• W4248351617 hasOpenAccess W4248351617 @default.
• W4248351617 hasPrimaryLocation W42483516171 @default.
• W4248351617 hasRelatedWork W1506200166 @default.
• W4248351617 hasRelatedWork W1995515455 @default.
• W4248351617 hasRelatedWork W2039318446 @default.
• W4248351617 hasRelatedWork W2048182022 @default.
• W4248351617 hasRelatedWork W2080531066 @default.
• W4248351617 hasRelatedWork W2748952813 @default.
• W4248351617 hasRelatedWork W2899084033 @default.
• W4248351617 hasRelatedWork W3031052312 @default.
• W4248351617 hasRelatedWork W3032375762 @default.
• W4248351617 hasRelatedWork W3108674512 @default.
• W4248351617 isParatext "false" @default.
• W4248351617 isRetracted "false" @default.
• W4248351617 workType "other" @default.